Search

Your search keyword '"Gramenzi, A"' showing total 12 results
Start Over Author "Gramenzi, A" Journal liver international
12 results on '"Gramenzi, A"'

1. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma

Author

Pecorelli, Anna, Lenzi, Barbara, Gramenzi, Annagiulia, Garuti, Francesca, Farinati, Fabio, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Felder, Martina, Morisco, Filomena, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Foschi, Francesco G., Biasini, Elisabetta, Masotto, Alberto, Virdone, Roberto, Bernardi, Mauro, Trevisani, Franco, Bolondi, Luigi, Biselli, Maurizio, Bucci, Laura, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Magalotti, Donatella, Serra, Carla, Venerandi, Laura, Giacomin, Anna, Maddalo, Gemma, Pozzan, Caterina, Vani, Veronica, Poggio, Paolo Del, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, DellʼIsola, Serena, Ialungo, Anna Maria, Bruzzone, Linda, Picciotto, Antonino, Marenco, Simona, Risso, Domenico, Sammito, Giorgio, Savarino, Vincenzo, Cammà, Calogero, Maida, Marcello, Costantino, Andrea, Barcellona, Maria Rosa, Affronti, Andrea, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, Cappa, Federica Mirici, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Missale, Gabriele, Porro, Emanuela, Guarino, Maria, Gemini, Stefano, and Schiadà, Laura

Published
2017
Full Text
View/download PDF

2. The evolutionary scenario of hepatocellular carcinoma in Italy: an update

Author

Bucci, Laura, Garuti, Francesca, Lenzi, Barbara, Pecorelli, Anna, Farinati, Fabio, Giannini, Edoardo G., Granito, Alessandro, Ciccarese, Francesca, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cammà, Calogero, Virdone, Roberto, Marra, Fabio, Felder, Martina, Morisco, Filomena, Benvegnù, Luisa, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Colecchia, Antonio, Bernardi, Mauro, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Napoli, Lucia, Negrini, Giulia, Piscaglia, Fabio, Serra, Carla, Tovoli, Francesco, Marafatto, Filippo, Murer, Francesca, Peserico, Giulia, Pozzan, Caterina, Vanin, Veronica, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Poggio, Paolo Del, Olmi, Stefano, de Matthaeis, Nicoletta, Balsamo, Claudia, Vavassori, Elena, Roselli, Paola, Dell’Isola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Barcellona, Maria Rosa, Cabibbo, Giuseppe, Costantino, Andrea, Maida, Marcello, Affronti, Andrea, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, Dall’Aglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Porro, Emanuela, Guarino, Maria, Gemini, Stefano, Schiadà, Laura, Chiaramonte, Maria, Marchetti, Fabiana, Valerio, Matteo, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Coccoli, Piero, Zamparelli, Marco Sanduzzi, Aburas, Sami, and Inghilesi, Andrea Lorenzo

Published
2017
Full Text
View/download PDF

7. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis

Author

GRAMENZI, ANNAGIULIA, GRANITO, ALESSANDRO, CUCCHETTI, ALESSANDRO, BOLONDI, LUIGI, BERNARDI, MAURO, TREVISANI, FRANCO, Golfieri R, Mosconi C, Cappelli A, Marinelli S, Pettinato C, Erroi V, Fiumana S, on behalf of BLOG, Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F, and on behalf of BLOG (Bologna Liver Oncology Group).

Subjects
Male, Niacinamide, Oncology, Sorafenib, medicine.medical_specialty, Carcinoma, Hepatocellular, Tare weight, medicine.medical_treatment, Antineoplastic Agents, Liver transplantation, ADVANCED STAGE, Cause of Death, Internal medicine, medicine, Humans, Yttrium Radioisotopes, HEPATOCELLULAR CARCINOMA, Propensity Score, Aged, Retrospective Studies, Aged, 80 and over, Hepatology, business.industry, Phenylurea Compounds, Liver Neoplasms, Middle Aged, medicine.disease, Embolization, Therapeutic, digestive system diseases, BCLC Stage, Treatment, Transplantation, SORAFENIB, Italy, Case-Control Studies, Hepatocellular carcinoma, Female, Liver function, Liver cancer, business, TRANSARTERIAL RADIOTHERAPY, medicine.drug
Abstract

Background & Aims: Sorafenib and transarterial 90 Y-radioembolization(TARE) are possible treatments for Barcelona Clinic Liver Cancer (BCLC)intermediate-advanced stage hepatocellular carcinoma (HCC). No studydirectly comparing sorafenib and TARE is currently available. This single-centre retrospective study compares the outcomes achieved with sorafeniband TARE in HCC patients potentially amenable to either therapy. Meth-ods: Seventy-four sorafenib (71 ± 10 years, male 87%, BCLC B/C 53%/47%)and 63 TARE HCC patients (66 ± 9 years, male 79%, BCLC B/C 41%/59%)were included based on the following criteria: Child–Pugh class A/B, perfor-mance status ≤1, HCC unfit for other effective therapies, no metastases andno previous systemic chemotherapy. Results: Median overall survivals of thetwo groups were comparable, being 14.4 months (95% CI: 4.3–24.5) in so-rafenib and 13.2 months (95% CI: 6.1–20.2) in TARE patients, with 1-, 2-and 3-year survival rates of 52.1%, 29.3% and 14.7% vs 51.8%, 27.8% and21.6% respectively. Two TARE patients underwent liver transplantation aftersuccessful down-staging. To minimize the impact of confounding factors onsurvival analysis, propensity model matched 32 patients of each group formedian age, tumour gross pathology and the independent prognostic factors(portal vein thrombosis, performance status, Model for End Liver Disease).Even after matching, the median survival did not differ between sorafenib(13.1 months; 95% CI: 1.2–25.9) and TARE patients (11.2 months; 95% CI:6.7–15.7), with comparable 1-, 2- and 3-year survival rates. Conclusions: Incirrhotic patients with intermediate-advanced or not-otherwise-treatableHCC, sorafenib and TARE provide similar survivals. Down-staging allowingliver transplantation only occurred after TARE.Hepatocellular carcinoma (HCC) is the third most com-mon cause of cancer-related death worldwide, and theleading cause of mortality of cirrhotic patients (1, 2).Several curative or palliative treatments are currentlyavailable, according to the cancer burden and liver func-tion. For this choice, American and European guidelinessuggest the use of the Barcelona Clinic Liver Cancer(BCLC) classification which links tumour stage to treat-ment in an evidence-based fashion (3, 4). Only 30–40%of HCCs are diagnosed at an early stage, and advancedstage HCCs (BCLC stage C) account for a large propor-tion of the remaining cases (5). Moreover, despite treat-ment, most early HCCs eventually progress to theadvanced stage. The recommended treatment for thesetumours is sorafenib, because two phase III clinical trialsproved that this treatment prolongs the survival ofChild–Pugh A patients with advanced HCC (6, 7).However, the tolerability of sorafenib is suboptimal, andin a post-marketing multicentre study, it was down-dosed in more than half of the patients and interruptedin 45% of cases, because of severe adverse effects (AEs)or liver function deterioration (8).As more than two-thirds of patients with advancedHCC die from intrahepatic tumour progression or liverfailure, rather than from metastatic disease (9–12), aneffective and well-tolerated locoregional treatment could

Published
2014
Full Text
View/download PDF

8. The changing scenario of hepatocellular carcinoma in Italy: an update.

Author

Garuti, Francesca, Neri, Andrea, Avanzato, Francesca, Gramenzi, Annagiulia, Rampoldi, Davide, Rucci, Paola, Farinati, Fabio, Giannini, Edoardo G., Piscaglia, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, and Svegliati‐Baroni, Gianluca

Subjects
LIVER cancer, LIVER analysis, CATHETER ablation, LIVER transplantation
Abstract

Background and aims: Epidemiology of hepatocellular carcinoma (HCC) is changing in most areas of the world. This study aimed at updating the changing scenario of aetiology, clinical presentation, management and prognosis of HCC in Italy during the last 15 years. Methods: Retrospective analysis of the Italian Liver Cancer (ITA.LI.CA) database included 6034 HCC patients managed in 23 centres from 2004 to 2018. Patients were divided into three groups according to the date of cancer diagnosis (2004‐2008, 2009‐2013 and 2014‐2018). Results: The main results were: (i) a progressive patient ageing; (ii) a progressive increase of non‐viral cases and, particularly, of 'metabolic' and 'metabolic + alcohol' HCCs; (iii) a slightly decline of cases diagnosed under surveillance, but with an incremental use of the semiannual schedule; (iv) a favourable cancer stage migration; (v) an increased use of radiofrequency ablation to the detriment of percutaneous ethanol injection; (vi) improved outcomes of ablative and transarterial treatments; (vii) an improved overall survival (adjusted for the lead time in surveyed patients) in the last calendar period, particularly in viral patients; (viii) a large gap between the number of potential candidates (according to oncologic criteria and age) to liver transplant and that of transplanted patients. Conclusions: During the last 15 years several aspects of HCC scenario have changed, as well as its management. The improvement in patient survival observed in the last period was likely because of a larger use of thermal ablation with respect to the less effective alcohol injection and to an improved management of intermediate stage patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

9. Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin

Author

A. Scuteri, Ranka Vukotic, Annagiulia Gramenzi, Carla Serra, Carmela Cursaro, Maurizio Biselli, Giovanni Vitale, Pietro Andreone, and Mauro Bernardi

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Hepatitis C virus, Ribavirin, virus diseases, medicine.disease, medicine.disease_cause, Chronic liver disease, Gastroenterology, digestive system diseases, Discontinuation, Virological response, chemistry.chemical_compound, chemistry, Interferon, Hepatocellular carcinoma, Internal medicine, medicine, business, medicine.drug
Abstract

We report here two cases of hepatocellular carcinoma (HCC) 90 and 70 months, respectively, after successful treatment with interferon (IFN) and ribavirin for hepatitis C virus (HCV)-related cirrhosis. A 50-year-old Caucasian man and a 66-year-old Caucasian woman with HCV-related cirrhosis were treated with IFN and ribavirin and in both cases a sustained virological response (SVR) was obtained with persistent normalization of serum aminotransferases and continuous disappearance of serum HCV-RNA. Both patients were subsequently followed up within an HCC surveillance programme based on biochemical and ultrasound (US) evaluation every 6 months and the appearance of HCC was detected 90 and 70 months, respectively, after discontinuation of therapy. We introduce these two cases to call attention to the importance of not underestimating the risk of HCC development even many years after complete HCV eradication, especially in the presence of established cirrhosis and concomitance of other risk factors for HCC.

Published
2007
Full Text
View/download PDF

10. A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18

Author

Biselli, Maurizio, primary, Dall'Agata, Marco, additional, Gramenzi, Annagiulia, additional, Gitto, Stefano, additional, Liberati, Caterina, additional, Brodosi, Lucia, additional, Ravaioli, Matteo, additional, Gambato, Martina, additional, Montalti, Roberto, additional, Pinna, Antonio D., additional, Burra, Patrizia, additional, Gerunda, Giorgio E., additional, Cillo, Umberto, additional, Andreone, Pietro, additional, and Bernardi, Mauro, additional

Published
2014
Full Text
View/download PDF

11. Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin

Author

Vukotic, Ranka, primary, Gramenzi, Annagiulia, additional, Vitale, Giovanni, additional, Cursaro, Carmela, additional, Serra, Carla, additional, Biselli, Maurizio, additional, Scuteri, Alessandra, additional, Andreone, Pietro, additional, and Bernardi, Mauro, additional

Published
2007
Full Text
View/download PDF

12. Reply to: 'Sorafenib or 90Y loaded resin microsphere radioembolization for locally-advanced hepatocellular carcinoma, what should we trust?'.

Author

Gramenzi, Annagiulia, Pettinato, Cinzia, Cappelli, Alberta, Mosconi, Cristina, Golfieri, Rita, and Trevisani, Franco

Subjects
*RADIOEMBOLIZATION, *LIVER cancer, *COHORT analysis
Abstract

A response from the authors of the article "Yttrium-90 radioembolization vs sorafenib for intermediatelocally advanced hepatocellular carcinoma: a cohort study with propensity score analysis" in 2015 issue is presented.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results